Lumos Pharma positive FDA End-of-Phase 2 meeting; Phase 3 trial plan with placebo control

LUMOS PHARMA, INC.

FDA agreed placebo-controlled design for LUM-201 Phase 3 trial; 2:1 randomization, ~150 patients, 6-month placebo arm.
Updated Phase 2 data show durable AHV: 12-month 8.2 cm/yr, 24-month 7.3 cm/yr (1.6 mg/kg) vs baseline 4.7 cm/yr.
Cash $23.2M at March 31, 2024; expected to fund operations through Q3 2024; Q1 net loss $10.4M vs $7.3M year-ago.
Full 12-month OraGrowtH212 data and additional analyses to be presented at ENDO in Q2 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

LUMOS PHARMA, INC. reported the quarter ended March 31, 2024 results: net income $10.4 million.

Period: the quarter ended March 31, 2024
Net income: $10.4 million
Result: reported results

Exact text from the filing

Net Loss – The net loss for the quarter ended March 31, 2024, was $10.4 million compared to a net loss of $7.3 million for the same period in 2023.

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

Source: SEC EDGAR

accession 0001126234-24-000059

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.